Viridian Therapeutics (NASDAQ:VRDN) (NASDAQ: VRDN) is a clinical-stage biotechnology company dedicated to the discovery and development of novel targeted therapies for severe and rare immuno-inflammatory diseases. Headquartered in Cambridge, Massachusetts, Viridian focuses on harnessing the power of monoclonal antibody engineering to address key receptor pathways implicated in tissue inflammation and remodeling. The company’s scientific approach aims to deliver high specificity and durable response while minimizing off-target effects common to broader immunosuppressive treatments.
The company’s lead investigational therapy, VRDN-001, is a fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R), a key driver of fibroblast activation and tissue expansion in thyroid eye disease (TED). By selectively blocking the IGF-1R pathway, VRDN-001 is designed to mitigate the painful and vision-threatening inflammation characteristic of TED. Viridian has reported clinical data demonstrating promising safety and preliminary efficacy, positioning VRDN-001 as a potential best-in-class option for patients who currently have limited treatment choices.
In addition to its lead program, Viridian is advancing a pipeline of next-generation receptor-targeted antibodies in various stages of preclinical development. These programs leverage the company’s proprietary antibody engineering platform to optimize tissue penetration, receptor engagement, and dosing profiles. Viridian’s research efforts extend across multiple immuno-inflammatory indications beyond ophthalmology, with an eye toward expanding into dermatology and other organ-specific inflammatory disorders.
Founded in 2019 by a team of experienced drug developers and immunology researchers, Viridian has assembled leadership with deep expertise in antibody therapeutics, clinical development, and regulatory affairs. Under the guidance of Chief Executive Officer Christiana Stamoulis, Ph.D., the company has built strategic partnerships and attracted investment from leading life-science venture firms. Viridian’s efforts are focused on advancing its clinical pipeline through pivotal studies and preparing for global regulatory submissions, with the ultimate goal of delivering transformative treatments to patients worldwide.
